Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Non-Current Liabilities: 2014-2024

Historic Total Non-Current Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 9 years, with Dec 2024 value amounting to $68.5 million.

  • Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities rose 15.01% to $71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.6 million, marking a year-over-year increase of 15.01%. This contributed to the annual value of $68.5 million for FY2024, which is 44.38% up from last year.
  • Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities amounted to $68.5 million in FY2024, which was up 44.38% from $47.4 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities' 5-year high stood at $68.5 million during FY2024, with a 5-year trough of $11.2 million in FY2020.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Total Non-Current Liabilities value was $47.4 million (recorded in 2023), while the average stood at $51.6 million.
  • Data for Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities shows a peak YoY spiked of 162.80% (in 2022) over the last 5 years.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities (Yearly) stood at $11.2 million in 2020, then surged by 32.30% to $14.8 million in 2021, then soared by 162.80% to $38.9 million in 2022, then rose by 22.03% to $47.4 million in 2023, then spiked by 44.38% to $68.5 million in 2024.